AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19859788 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavior group therapy (CBT)
Number of subjects: 30
Study 18333863 — intervention group
Group type: EXPERIMENTAL
Intervention: Saquinavir (SQV; 1200 mg t.i.d.)
Number of subjects: 0
Study 18333863 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketoconazole (400 mg q.d.)
Number of subjects: 0
Study 18333863 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted lopinavir (LPV/r; 400 mg/100 mg b.i.d.)
Number of subjects: 0
Study 18333863 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted saquinavir (SQV/r; 1000 mg/100 mg b.i.d.)
Number of subjects: 0
Study 18333863 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ritonavir (RTV; 100 mg b.i.d.)
Number of subjects: 0
Study 18333863 — intervention group
Group type: EXPERIMENTAL
Intervention: Atazanavir (ATZ; 400 mg q.d.)
Number of subjects: 0
Study 18333863 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted atazanavir (ATZ/r; 300 mg/100 mg b.i.d.)
Number of subjects: 0
Study 18333863 — intervention group
Group type: EXPERIMENTAL
Intervention: Ritonavir-boosted tipranavir (TPV/r; 500 mg/200 mg b.i.d.)
Number of subjects: 0
Study 18333863 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc (100 mg b.i.d.)
Number of subjects: 0
Study 16203030 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation counseling according to an intensified minimal intervention strategy
Number of subjects: 392
Study 16203030 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 392
Study 12401633 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 1.5 mg/kg with epinephrine 5 microg/mL
Number of subjects: 24
Study 12401633 — intervention group
Group type: COMPARATOR
Intervention: Epidural ropivacaine 1.5 mg/kg without epinephrine (plain group)
Number of subjects: 24
Study 10621575 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term income support, long-term work-search waivers, and on-call advice
Number of subjects: 0
Study 10621575 — intervention group
Group type: COMPARATOR
Intervention: Capital infusions and up-front classes
Number of subjects: 0
Study 7546757 — intervention group
Group type: EXPERIMENTAL
Intervention: C6 stellate ganglion nerve block with radiocontrast and local anesthetic (5 ml increments to 20 ml total volume)
Number of subjects: 10
Study 7546757 — intervention group
Group type: EXPERIMENTAL
Intervention: C7 stellate ganglion nerve block with radiocontrast and local anesthetic (5 ml increments to 20 ml total volume)
Number of subjects: 10
Study 7546757 — intervention group
Group type: EXPERIMENTAL
Intervention: C6 stellate ganglion nerve block
Number of subjects: 10
Study 2360541 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.0 mg pyridoxine
Number of subjects: 40
Study 2360541 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg pyridoxine
Number of subjects: 40
Study 2360541 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 mg zinc
Number of subjects: 40
Study 2360541 — intervention group
Group type: COMPARATOR
Intervention: 0 mg zinc
Number of subjects: 40
Study 343182 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 gel
Number of subjects: 0
Study 343182 — intervention group
Group type: COMPARATOR
Intervention: Conventional practices (amniotomy and intravenous oxytocin infusion or oral prostaglandin therapy)
Number of subjects: 0
Study 31282092 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple-based cognitive behavioural intervention (CBI)
Number of subjects: 388
Study 31282092 — intervention group
Group type: COMPARATOR
Intervention: Women-alone CBI
Number of subjects: 388
Study 31282092 — intervention group
Group type: COMPARATOR
Intervention: Control (standard perinatal care)
Number of subjects: 388
Study 30959753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooked Brassica carinata leaves
Number of subjects: 22
Study 30959753 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw Brassica carinata leaves
Number of subjects: 22
Study 30959753 — intervention group
Group type: COMPARATOR
Intervention: Baseline (no intervention)
Number of subjects: 22
Study 27908604 — intervention group
Group type: EXPERIMENTAL
Intervention: Phospholipid liposomal spray (Tears Again®) applied to one eye four times daily for two weeks.
Number of subjects: 31
Study 27908604 — intervention group
Group type: COMPARATOR
Intervention: Control eye (no treatment).
Number of subjects: 31
Study 26104939 — intervention group
Group type: EXPERIMENTAL
Intervention: RT plus total androgen suppression (TAS)
Number of subjects: 1979
Study 26104939 — intervention group
Group type: COMPARATOR
Intervention: RT alone
Number of subjects: 1979
Study 23915015 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) - 10 sessions
Number of subjects: 251
Study 23915015 — intervention group
Group type: COMPARATOR
Intervention: Sertraline (SER) - 50-200 mg/d
Number of subjects: 251
Study 23915015 — intervention group
Group type: COMPARATOR
Intervention: Both groups received diabetes treatment as usual
Number of subjects: 251
Study 23915015 — intervention group
Group type: COMPARATOR
Intervention: Hamilton Depression Rating Scale (HAMD)
Number of subjects: 251
Study 21995387 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid
Number of subjects: 3360
Study 21995387 — intervention group
Group type: COMPARATOR
Intervention: Control (standard adjuvant systemic therapy without zoledronic acid)
Number of subjects: 3360
Study 19187370 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg mifepristone
Number of subjects: 2181
Study 19187370 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg mifepristone
Number of subjects: 2181
Study 19187370 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-hour interval to misoprostol administration
Number of subjects: 2181
Study 19187370 — intervention group
Group type: EXPERIMENTAL
Intervention: 48-hour interval to misoprostol administration
Number of subjects: 2181
Study 19187370 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse effects
Number of subjects: 2181
Study 17083172 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition NN (sports wheelchair on a tartan surface)
Number of subjects: 11
Study 17083172 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition RN (increased mechanical resistance)
Number of subjects: 11
Study 17083172 — intervention group
Group type: EXPERIMENTAL
Intervention: Condition RD (limited turning capacity)
Number of subjects: 11
Study 15186939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin at 800 microg/kg given at 3-monthly intervals
Number of subjects: 0
Study 15186939 — intervention group
Group type: COMPARATOR
Intervention: Ivermectin at 150 microg/kg given annually
Number of subjects: 0
Study 15186939 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivermectin at high doses (800 microg/kg)
Number of subjects: 0
Study 11302289 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 8mg or 16mg
Number of subjects: 185
Study 11302289 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (HCTZ) 12.5mg
Number of subjects: 185
Study 9453273 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 10 mg
Number of subjects: 57
Study 9453273 — intervention group
Group type: EXPERIMENTAL
Intervention: Zolmitriptan 5 mg
Number of subjects: 57
Study 9453273 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 57
Study 9453273 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexfenfluramine 15 mg
Number of subjects: 57
Study 9453273 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 1.25 mg
Number of subjects: 57
Study 9453273 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 57
Study 7876396 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 mg oral dose of metronidazole
Number of subjects: 12
Study 7876396 — intervention group
Group type: COMPARATOR
Intervention: 5 g of 0.75% metronidazole intravaginal gel (37.5 mg metronidazole)
Number of subjects: 12
Study 3340942 — intervention group
Group type: EXPERIMENTAL
Intervention: Ioxaglate
Number of subjects: 120
Study 3340942 — intervention group
Group type: COMPARATOR
Intervention: Iopamidol
Number of subjects: 120
Study 31356278 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX perioperative chemotherapy (4 cycles before surgery and 8 cycles after)
Number of subjects: 120
Study 31356278 — intervention group
Group type: COMPARATOR
Intervention: Control group (6 months of adjuvant FOLFOX after colectomy)
Number of subjects: 120
Study 29798778 — intervention group
Group type: EXPERIMENTAL
Intervention: O-SES (Sirolimus-Eluting Stent)
Number of subjects: 452
Study 29798778 — intervention group
Group type: COMPARATOR
Intervention: X-EES (Everolimus-Eluting Stent)
Number of subjects: 452
Study 29798778 — intervention group
Group type: EXPERIMENTAL
Intervention: O-SES
Number of subjects: 452
Study 29798778 — intervention group
Group type: COMPARATOR
Intervention: X-EES
Number of subjects: 452
Study 29798778 — intervention group
Group type: EXPERIMENTAL
Intervention: O-SES (in diabetic patients)
Number of subjects: 452
Study 29798778 — intervention group
Group type: COMPARATOR
Intervention: X-EES (in diabetic patients)
Number of subjects: 452
Study 29798778 — intervention group
Group type: EXPERIMENTAL
Intervention: O-SES (in small vessels)
Number of subjects: 452
Study 29798778 — intervention group
Group type: COMPARATOR
Intervention: X-EES (in small vessels)
Number of subjects: 452
Study 26780673 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual schema therapy (ST)
Number of subjects: 25
Study 26780673 — intervention group
Group type: COMPARATOR
Intervention: Attention control condition (exploration phase)
Number of subjects: 25
Study 26780673 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control condition (baseline phase)
Number of subjects: 25
Study 25710460 — intervention group
Group type: EXPERIMENTAL
Intervention: 24,25(OH)2D3
Number of subjects: 0
Study 25710460 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 23099196 — intervention group
Group type: EXPERIMENTAL
Intervention: Cellulose (CE) membranes
Number of subjects: 21
Study 23099196 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymethylacrylate (PMMA) membranes
Number of subjects: 21
Study 23099196 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (CON)
Number of subjects: 21
Study 20812121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative probability information on Chlamydia
Number of subjects: 0
Study 20812121 — intervention group
Group type: EXPERIMENTAL
Intervention: Single incident probability information on Chlamydia
Number of subjects: 0
Study 20812121 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative probability information on HIV
Number of subjects: 0
Study 20812121 — intervention group
Group type: EXPERIMENTAL
Intervention: Single incident probability information on HIV
Number of subjects: 0
Study 18379232 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg every 8 hrs via a 4‐hr intravenous infusion
Number of subjects: 531
Study 18379232 — intervention group
Group type: COMPARATOR
Intervention: Imipenem 500 mg every 6 hrs or 1000 mg every 8 hrs via 30‐ or 60‐min intravenous infusions
Number of subjects: 531
Study 18379232 — intervention group
Group type: EXPERIMENTAL
Intervention: Doripenem for patients with Pseudomonas aeruginosa
Number of subjects: 531
Study 18379232 — intervention group
Group type: COMPARATOR
Intervention: Imipenem for patients with Pseudomonas aeruginosa
Number of subjects: 531
Study 18379232 — intervention group
Group type: COMPARATOR
Intervention: Doripenem vs Imipenem
Number of subjects: 531
Study 16635650 — intervention group
Group type: EXPERIMENTAL
Intervention: 35% CO2/65% O2 mixture
Number of subjects: 91
Study 16635650 — intervention group
Group type: COMPARATOR
Intervention: Atmospheric compressed air
Number of subjects: 91
Study 12789182 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermasanding treatment
Number of subjects: 15
Study 12789182 — intervention group
Group type: COMPARATOR
Intervention: Control (unsanded side)
Number of subjects: 15
Study 10663454 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 100,240 2.5 mg orally, q.d. for 8 days
Number of subjects: 12
Study 10663454 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 100,240 10 mg orally, q.d. for 8 days
Number of subjects: 12
Study 10663454 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 100,240 20 mg orally, q.d. for 8 days
Number of subjects: 12
Study 10663454 — intervention group
Group type: EXPERIMENTAL
Intervention: MDL 100,240 (oral solution)
Number of subjects: 12
Study 8801396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (20-80 mg/day)
Number of subjects: 59
Study 8801396 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg b.i.d.)
Number of subjects: 59
Study 8801396 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin + cholestyramine
Number of subjects: 59
Study 8801396 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil + cholestyramine
Number of subjects: 59
Study 1906434 — intervention group
Group type: EXPERIMENTAL
Intervention: metoprolol OROS 21/285
Number of subjects: 53
Study 1906434 — intervention group
Group type: COMPARATOR
Intervention: atenolol 100 mg
Number of subjects: 53
Study 6849734 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime chenic acid 8 mg kg‐1 day‐1
Number of subjects: 7
Study 6849734 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium acetyl salicylate 600 mg four times daily
Number of subjects: 7
Study 6849734 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedtime chenic acid 8 mg kg‐1 day‐1 plus sodium acetyl salicylate
Number of subjects: 7
Study 6849734 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 7
Study 31399378 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated varicella zoster virus vaccine (VZV)
Number of subjects: 5286
Study 31399378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5286
Study 28544704 — intervention group
Group type: EXPERIMENTAL
Intervention: Treat-to-target
Number of subjects: 532
Study 28544704 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 532
Study 27749141 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of haloperidol and midazolam
Number of subjects: 195
Study 27749141 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol alone
Number of subjects: 195
Study 24782093 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin combined with paclitaxel and cisplatin (ATP)
Number of subjects: 86
Study 24782093 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel and cisplatin (TP)
Number of subjects: 86
Study 22779281 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral-B Precision Clean (PC) brush head
Number of subjects: 267
Study 22779281 — intervention group
Group type: COMPARATOR
Intervention: Store Brand Easyflex (SB) brush head
Number of subjects: 267
Study 22779281 — intervention group
Group type: COMPARATOR
Intervention: Laboratory cleaning efficacy test using worn brush heads
Number of subjects: 267
Study 21058476 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut implantation
Number of subjects: 74
Study 21058476 — intervention group
Group type: COMPARATOR
Intervention: Fenofibrate
Number of subjects: 74
Study 17929519 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed loading (4 months after implant insertion)
Number of subjects: 30
Study 17929519 — intervention group
Group type: EXPERIMENTAL
Intervention: Early loading (1 week after implant surgery)
Number of subjects: 30
Study 17929519 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate loading (day of or day after surgery)
Number of subjects: 30
Study 17929519 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the comparison between loading times)
Number of subjects: 30
Study 15711660 — intervention group
Group type: EXPERIMENTAL
Intervention: High intra-abdominal pressure
Number of subjects: 22
Study 15711660 — intervention group
Group type: EXPERIMENTAL
Intervention: Low intra-abdominal pressure
Number of subjects: 22
Study 11257249 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg weekly
Number of subjects: 60
Study 11257249 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg twice a week
Number of subjects: 60
Study 11257249 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg twice a week for 12 weeks followed by 30 mg weekly
Number of subjects: 60
Study 11257249 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg twice a week for 6 weeks followed by 30 mg weekly
Number of subjects: 60
Study 11257249 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg weekly
Number of subjects: 60
Study 11257249 — intervention group
Group type: EXPERIMENTAL
Intervention: Single 60 mg loading dose followed by 30 mg weekly doses
Number of subjects: 60
Study 11257249 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg weekly (Dosage regimen VI)
Number of subjects: 60
Study 11257249 — intervention group
Group type: COMPARATOR
Intervention: 30 mg twice a week for 12 weeks (Dosage regimen III)
Number of subjects: 60
Study 9886194 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate (2mg/kg/day for five days, then 1 mg/kg/day for two days: total=12 mg/kg)
Number of subjects: 443
Study 9886194 — intervention group
Group type: COMPARATOR
Intervention: Artemether (4 mg/kg followed by 2 mg/kg/day for two days, then 1 mg/kg/day for four days: total=12 mg/kg)
Number of subjects: 443
Study 9886194 — intervention group
Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 443
Study 9886194 — intervention group
Group type: COMPARATOR
Intervention: Artemether
Number of subjects: 443
Study 9886194 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 443
Study 8002848 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug intervention to lower cholesterol levels
Number of subjects: 0
Study 8002848 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid intervention
Number of subjects: 0
Study 2534822 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlormezanone
Number of subjects: 46
Study 2534822 — intervention group
Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 46
Study 2534822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 7698136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (titrated from 1.25 mg to a maximum of 10 mg once daily over 4 weeks, mean dose 8 mg)
Number of subjects: 223
Study 7698136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223
Study 7698136 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 223
Study 699938 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous practolol 15 mg followed by oral practolol 200 mg at 12 h intervals
Number of subjects: 94
Study 699938 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous practolol
Number of subjects: 94
Study 699938 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 94
Study 31820551 — intervention group
Group type: EXPERIMENTAL
Intervention: RLP+ (Reproductive Life Planning with contraceptive action planning)
Number of subjects: 984
Study 31820551 — intervention group
Group type: EXPERIMENTAL
Intervention: RLP (Reproductive Life Planning)
Number of subjects: 984
Study 31820551 — intervention group
Group type: COMPARATOR
Intervention: Information only (Control group)
Number of subjects: 984
Study 27716513 — intervention group
Group type: EXPERIMENTAL
Intervention: Chamomile extract
Number of subjects: 0
Study 24395083 — intervention group
Group type: EXPERIMENTAL
Intervention: reading intervention (50 minutes a day in small groups)
Number of subjects: 0
Study 24395083 — intervention group
Group type: COMPARATOR
Intervention: business as usual (BAU) condition
Number of subjects: 0
Study 23838912 — intervention group
Group type: EXPERIMENTAL
Intervention: Early postoperative enteral immunonutrition (formula supplemented with arginine, omega‐3 fatty acids and RNA)
Number of subjects: 109
Study 23838912 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric-isonitrogenous control
Number of subjects: 109
Study 22436475 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine (IAL) - 4 mg/kg (up to 200 mg) of 1% lidocaine injected into the glenohumeral joint.
Number of subjects: 44
Study 22436475 — intervention group
Group type: COMPARATOR
Intervention: Intravenous sedation (IVS) - medications for sedation as per physician discretion.
Number of subjects: 44
Study 22436475 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (IAL and IVS).
Number of subjects: 44
Study 19018157 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 50 mg weekly
Number of subjects: 33
Study 19018157 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 17588424 — intervention group
Group type: EXPERIMENTAL
Intervention: Spyder aortic connector
Number of subjects: 22
Study 17588424 — intervention group
Group type: COMPARATOR
Intervention: Hand-sewn technique
Number of subjects: 22
Study 15450562 — intervention group
Group type: EXPERIMENTAL
Intervention: T(3) 125 microg/day orally for 7 days preoperatively and from the first postoperative day till discharge
Number of subjects: 80
Study 15450562 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 11842271 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate supplementation (5-day load of 0.3 g/kg(-1) x day(-1) followed by a 5-week maintenance dose of 0.03 g/kg(-1) x day(-1))
Number of subjects: 22
Study 11842271 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate supplementation (5-week maintenance dose)
Number of subjects: 22
Study 11842271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11842271 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate supplementation
Number of subjects: 22
Study 9788454 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (1.25 to 5.00 mg/day)
Number of subjects: 97
Study 9788454 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus conventional antihypertensive therapy
Number of subjects: 97
Study 8002083 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin treatment
Number of subjects: 34
Study 8002083 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 34
Study 2969551 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin therapy combined with anti-thrombosis stockings
Number of subjects: 286
Study 2969551 — intervention group
Group type: COMPARATOR
Intervention: Heparin therapy alone
Number of subjects: 286